Protective effect of amlodipine against osteoporosis in stroke-prone spontaneously hypertensive rats

European Journal of Pharmacology

Volumn 635, Issue 1-3, 2010, Pages 227-230

  Ushijima, Kentarou ^a   Liu, Yuwang ^a   Maekawa, Tomohiro ^a   Ishikawa, Eiko ^a   Motosugi, Yuya ^a   Ando, Hitoshi ^a   Tsuruoka, Shu ichi ^b   Fujimura, Akio ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Amlodipine; Hypertension; Osteoclast; Osteoporosis; Parathyroid hormone

Indexed keywords

AMLODIPINE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; PARATHYROID HORMONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; BONE DENSITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; FEMUR; MALE; NONHUMAN; OSTEOCLAST; OSTEOPOROSIS; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT;

ADMINISTRATION, ORAL; AMLODIPINE; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BONE DENSITY; CALCIUM; COLLAGEN TYPE I; DISEASE SUSCEPTIBILITY; DRUG ADMINISTRATION SCHEDULE; FEMUR; MALE; OSTEOPOROSIS; PARATHYROID HORMONE; PEPTIDES; RATS; RATS, INBRED SHR; STROKE;

EID: 77952321015     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.02.039     Document Type: Article

References (20)

1. Aubin J.E., Bonnelye E. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos. Int. 2000, 11:905-913.
2. Baggio B., Gambaro G., Marchini F., Cicerello E., Borsatti A. Effect of nifedipine on urinary calcium and oxalate excretion in renal stone formers. Nephron 1986, 43:234-235.
3. Caló L., Cantaro S., Piccoli A., d'Angelo A., Giannini S., Williams H.E., Borsatti A. Effect of nifedipine on urinary excretion of calcium and calcium-controlling hormones in essential hypercalciuria. Cardiovasc. Drugs Ther. Suppl. 1990, 5:983-986.
4. Cappuccio F.P., Meilahn E., Zmuda J.M., Cauley J.A. High blood pressure and bone-mineral loss in elderly white women: a prospective study. Study of Osteoporotic Fractures Research Group. Lancet 1999, 354:971-975.
5. Christgau S., Bitsch-Jensen O., Bjarnason H.N., Henriksen G.E., Qvist P., Alexandersen P., Henriksen B.D. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 2000, 26:505-511.
6. Dempster D.W. Bone remodeling. Disorders of Bone and Mineral Metabolism 1992, 355-380. Raven press, New York. F.L. Coe, M.J. Favus (Eds.).
7. Eyre D.R. Bone biomarkers as tools in osteoporosis management. Spine 1997, 22:17S-24S.
8. Fukuda S., Tsuchikura S., Iida H., Ikeda K., Nara Y., Yamori Y. Intestinal calcium absorption and response of calcium regulating hormones in the stroke-prone spontaneously hypertensive rat as a model of osteoporosis. Clin. Exp. Pharmacol. Physiol. Suppl. 1995, 22:S240-S241.
9. Halabe A., Wong N.L., Sutton R.A. The effect of verapamil and thiazide in the prevention of renal stone formation. Urol. Res. 1990, 18:155-158.
10. Halici Z., Borekci B., Ozdemir Y., Cadirci E., Suleyman H. Protective effects of amlodipine and lacidipine on ovariectomy-induced bone loss in rats. Eur. J. Pharmacol. 2008, 579:241-245.
11. Horikawa Y., Nakajima H., Iizuka K., Imagawa A., Tomita K., Shiba E., Takai S., Miyagawa J., Kuwajima M., Namba M., Hanafusa T., Matsuzawa Y. In vivo effects of calcium entry blockers on human parathyroid adenoma cells with special reference to calcium sensing ability and the hormone secretion. Res. Commun. Mol. Pathol. Pharmacol. 1999, 106:87-96.
12. Rejnmark L., Vestergaard P., Mosekilde L. Reduced fracture risk in users of thiazide diuretics. Calcif. Tissue Int. 2005, 76:167-175.
13. Rejnmark L., Vestergaard P., Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J. Hypertens. 2006, 24:581-589.
14. Ritchie C.K., Maercklein P.B., Fitzpatrick L.A. Direct effect of calcium channel antagonists on osteoclast function: alterations in bone resorption and intracellular calcium concentrations. Endocrinology 1994, 135:996-1003.
15. Suda T., Takahashi N., Udagawa N., Jimi E., Gillespie M.T., Martin T.J. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 1999, 20:345-357.
16. Tsuda K., Nishio I., Masuyama Y. Bone mineral density in women with essential hypertension. Am. J. Hypertens. 2001, 14:704-707.
17. Tsuruoka S., Nishiki K., Sugimoto K., Fujimura A. Time of day improves efficacy and reduces adverse reactions of vitamin D3 in 5/6 nephrectomized rat. Life Sci. 2002, 71:1809-1820.
18. Tsuruoka S., Wakaumi M., Yamamoto H., Fujimura A. Chronopharmacology of oxacalcitriol in rat model of osteoporosis. Eur. J. Pharmacol. 2004, 488:239-245.
19. Vestergaard P., Rejnmark L., Mosekilde L. Hypertension is a risk factor for fractures. Calcif. Tissue Int. 2009, 84:103-111.
20. Yamori Y., Fukuda S., Tsuchikura S., Ikeda K., Nara Y., Horie R. Stroke-prone SHR (SHRSP) as a model for osteoporosis. Clin. Exp. Hypertens. 1991, 13:755-762.